Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab

NCT06322667 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT06322667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06322667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
Lead sponsor
Eisai Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
February 14, 2024
Completion date
December 31, 2027
Enrollment
5,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease